Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald
CEO & Managing Director, Dr Tony Keating
Source: ResApp Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mobile healthcare company ResApp Health (RAP) has received a research and development (R&D) tax refund of more than $707,000
  • The company also received an Export Market Development Grant (EMDG) of nearly $94,000, bringing an extra $801,000 to its cash balance
  • The EMDG is an Australian financial assistance program for aspiring and current exporters
  • ResApp had a busy FY20, launching SleepCheck for sleep apnoea sufferers and teaming up with Phenix Health
  • RAP last received a tax refund in December 2019, which totalled $1.8 million
  • Shares in ResApp are down 1.47 per cent on the market and are trading at 6.7 cents

Mobile healthcare company ResApp Health (RAP) has received a research and development (R&D) tax refund of $707,744.

The R&D tax refund falls under the Australian Government's Research and Development Tax Incentive Scheme and relates to R&D activities undertaken throughout FY20.

The company also received an Export Market Development Grant (EMDG) of $93,994, bringing an extra $801,738 to its cash balance.

The EMDG is an Australian financial assistance program for aspiring and current exporters. It is not limited to healthcare but spans a range of industries.

ResApp had a busy FY20, launching SleepCheck for sleep apnoea sufferers, teaming up with Phenix Health, and receiving Therapeutic Goods Administration (TGA) approval for its ResAppDx-EU version 2 app.

ResApp has developed a mobile software device, ResAppDx-EU, which is used by clinicians for the diagnosis of multiple respiratory problems.

It uses machine learning algorithms to analyse a patient's cough sounds to diagnose diseases and provide quick and accurate information.

It is a software-only solution that can run on smartphones, meaning it does not require any additional hardware or accessories.

ResApp last received a tax refund in December 2019, which totalled $1.8 million.

Shares in ResApp are down 1.47 per cent on the market and are trading at 6.7 cents at 11:28 am AEDT.

RAP by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) launches ecommerce channels, enters Polish markets

Creso Pharma (CPH) has launched new e-commerce channels and expanded into Poland with a maiden purchase order secured.
Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

" Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

Emyria (EMD) has appointed a consultant to support its psychedelic-assisted therapy programs.
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) ticks off another distribution deal for EuGeni

AnteoTech (ADO) has signed a distribution agreement with Ramma Dental for its EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT).
Healthia (ASX:HLA) - CEO, Wesley Coote - The Market Herald

" Healthia (ASX:HLA) up on Rothwell Physiotherapy buy

Healthia (HLA) shares have enjoyed a 10 per cent rise after reporting a $1.62 million acquisition of Queensland’s Rothwell Physiotherapy.